

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231, ON THE DATE INDICATED BELOW.



*Victoria A Jones*

DATE:

*12/11/01*

PATENT

RECEIVED

FEB 07 2002

TECH CENTER 1600/290

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Re:

Patent Application of  
Stanley Stewart DAVIS *et al.*

: Group Art Unit: 1615

Conf. No.: 6578

Appln. No.: 09/841,228

: Examiner: Sharon Howard

Filed: April 24, 2001

For: NASAL DRUG DELIVERY  
COMPOSITION

: Attorney Docket  
: No. 8567-604US  
: (WESR/P21724US)

**AMENDMENT**

In response to the Office Action mailed September 11, 2001 (Paper No. 6), please consider the following remarks and amendments. This response is timely filed on December 11, 2001.

**In the Specification:**

Please amend the specification as follows:

Please replace paragraph [0001] of the specification in accordance with 37 C.F.R.

§ 1.121(b)(1) to read as follows:

**[0001]** This application is a continuation of International Application No.

*Al* PCT/GB99/03489, filed October 21, 1999, and published in the English language on May 4, 2000, under International Publication No. WO 00/24373, the disclosure of which is incorporated herein by reference.

**In the Claims:**

Please delete claims 12-14, without prejudice.

Please amend claims 1, 2, 5-7, 10, and 11, to read as follows:

*Sub B1* *A2* 1. (Amended) A pharmaceutical composition adapted for nasal administration